Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composition for treating diseases caused by fat deposition and application of drug composition

A fat accumulation and composition technology, applied in the medical field, can solve problems such as discomfort

Active Publication Date: 2018-03-30
YANBIAN UNIV
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these purely synthetic drugs have many side effects, including dry mouth, anorexia, insomnia and gastrointestinal discomfort, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composition for treating diseases caused by fat deposition and application of drug composition
  • Drug composition for treating diseases caused by fat deposition and application of drug composition
  • Drug composition for treating diseases caused by fat deposition and application of drug composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1 Effects of Compounds 1-12 on the Survival Rate of 3T3-L1 Preadipocytes

[0036] The effect of 12 monomeric compounds on the survival rate of 3T3-L1 cells was detected by MTS method, specifically:

[0037] (1) In a 96-well plate, add 100 μL of culture medium containing 3T3-L1 preadipocytes to each well. The cells were grown in the 96-well plate and covered the bottom of the plate, the original culture medium was discarded, and 200 μL of drugs diluted with DMEM medium (respectively compounds 1-12) were added to each well, and the final concentrations of the drugs were 10, 20, and 40 , 80 μmol / L. Place the treated cells at 37°C, 5% CO 2 Continue to grow under the conditions. After 96 hours, the original culture medium was discarded, 15 μL of MTS solution was added to each well, and the wells were placed in the dark at 37°C for 1 hour. The absorbance A value was measured at a wavelength of 490 nm in a microplate reader (infinite M200PRO, TECAN, Switzerland). ...

Embodiment 2

[0040] Example 2 Effects of Compounds 1-12 on the Differentiation of 3T3-L1 Preadipocytes

[0041] (1) Induction and differentiation of 3T3-L1 preadipocytes

[0042]3T3-L1 preadipocytes were subcultured into 6-well plates and cultured with high-glucose DMEM medium containing 10% FCS. When the cells adhered to the wall and grew to cover the 6-well plate (defined as day 0), they were induced to differentiate. Set up a group of normal group (Con group, add 10% FCS medium); 5% FBS+high sugar DMEM); Set up a group of fat differentiation positive control group (PIO group, add inducing differentiation agent I+10 μ mol / L pioglitazone); Each sample experimental group adds inducing differentiation agent I, and preparation final concentration is respectively: 1, Compounds 4 and 9 were all 10 μmol / L, and compounds 2, 3, 5, 6, 7, 8, 10, 11, and 12 were all 20 μmol / L, and cultured for 4 days. On day 4, the culture medium was replaced. The Con group was replaced with fresh 10% FCS cultur...

Embodiment 3

[0051] Example 3 Effects of Compounds 1-12 on Triglyceride Content in HepG2 Cells

[0052] (1) MTS cytotoxicity test

[0053] Through the MTS experiment, the non-toxic concentration of 12 monomeric compounds to HepG2 cells was determined. The results showed that compound 5 was 0-5 μmol / L, compound 12 was 0-10 μmol / L, compound 7 was 0-20 μmol / L, , 2, 3, 6, and 8 in the range of 0-40 μmol / L, and compounds 4, 9, 10, and 11 in the concentration range of 0-80 μmol / L, the cell survival rate reached more than 95%, that is, there was no obvious effect on cell proliferation, that is No toxic effect on cells. Therefore, the cells were treated with corresponding concentrations of drugs, respectively.

[0054] (2) Determination of triglyceride content

[0055] HepG2 cells were seeded in 6-well plates (1×10 6 cells / well) were cultured in DMEM medium containing 10% FBS. When the cells adhere to the wall and grow to cover the 6-well plate, add compounds 1 to 12 at a certain concentratio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composition for preventing and / or treating diseases caused by fat deposition. The drug composition comprises acacetin and synergistic compounds of the acacetin, whereinthe synergistic compounds include one or more of jaceosidin, kaempferol, chrysoeriol, quercetin, apigenin, hispidulin, luteolin, quercitrin, rutin, isorhamnetin and genkwanin. The acacetin can obviously inhibit 3T3-L1 preadipocyte differentiation, when the acacetin is combined with the synergistic compounds in use, the inhibition effect of the acacetin can be obviously enhanced, the use amount ofthe acacetin and the synergistic compounds can be obviously reduced, and the cost of the preparation is reduced. The drug composition can be used for treating and preventing the diseases caused by fatdeposition.

Description

technical field [0001] The invention belongs to the medical field, and in particular relates to a pharmaceutical composition for treating / and preventing fat accumulation diseases such as obesity and fatty liver and its application. Background technique [0002] Obesity has become a very modern hot topic, spreading around the world, seriously threatening human health, and increasing the burden of social and economic development. In Western countries such as Europe and the United States, obesity has become the fourth largest medical and social problem in the world in recent years, and the top three are drug abuse, alcoholism and AIDS. The obesity population in the United States and China ranks first and second in the world, and the direct consumption and indirect costs of obesity exceed 100 billion U.S. dollars each year. [0003] Normal functioning adipocytes are crucial in maintaining energy and metabolic homeostasis, while excess adipocytes often lead to dysregulation of a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/352A61P3/04A61P1/16A61P3/06A61P3/10A61P9/10A61P9/12A61P19/00A61P21/00
CPCA61K31/352A61K45/06A61K2300/00
Inventor 元海丹朴光春
Owner YANBIAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com